THE INDIAN PHARMACIST Official Circular Pharmacy Logo THE INDIAN PHARMACISTLearn. Explore. Practise. Excel.
MEDICINE MONOGRAPH CODE: [8.10] ID: TIP-MED-000138

Doxycycline Hydrochloride / Hyclate

Active Ingredient / Scientific Identity: Doxycycline Hydrochloride / Hyclate • Class: Tetracycline Antibiotic (Lipophilic Bacteriostatic 30S Ribosomal Subunit Inhibitor; WHO 'Access' Group)

⚖️ Compare Profile
Generic / Entity NameDoxycycline Hydrochloride / Hyclate ([8.10])
Verified Indian Brands / RefGeneric Compendial Entry (No Commercial Brand Claimed)
Pharmacological ClassTetracycline Antibiotic (Lipophilic Bacteriostatic 30S Ribosomal Subunit Inhibitor; WHO 'A
Available Dosage FormsOral Capsules / Film-Coated Tablets: 100 mg (also 200 mg loading strength; 40 mg sub-antimicrobial rosacea dos
Regulatory ClassificationSchedule H Prescription Drug (To be sold by retail on the prescription of a Registere
Key Warning & Review DateRenal: SAFEST TETRACYCLINE IN CKD — excreted via non-renal biliary and GI diffusion as an inactive chelate; NO dose adjustmen
Reviewed: 2026-11-10
Safety Matrix:⚖️ Legal Status: Schedule H Prescription Drug (To be sold by retail o✔️ Standard Clinical Dispensing Precautions

1. Clinical & Scientific Overview

Doxycycline Hydrochloride / Hyclate (TIP-MED-000138, Reference Code [8.10]) is classified under Antimicrobials — Antibacterial & Antibiotic Agents (Ch 08) as a Tetracycline Antibiotic (Lipophilic Bacteriostatic 30S Ribosomal Subunit Inhibitor; WHO 'Access' Group). Within the Indian regulatory and compendial framework, it is governed under Schedule H Prescription Drug (To be sold by retail on the prescription of a Registered Medical Practitioner only — Drugs Rules 1945).

Verified Indian Market Examples / Compendial Status:
Representative Indian Market Examples (Edition 2.7 Ch 08 [8.10], p. 97): Doxt-SL (Dr. Reddy's—contains Lactic Acid Bacillus), Microdox-LBX (Micro Labs), Doxy-1 (USV), Minym, Vibromycin — Strengths & Dosage Forms: Oral Capsules / Film-Coated Tablets: 100 mg (also 200 mg loading strength; 40 mg sub-antimicrobial rosacea dose)
Representative Indian Market Examples (Edition 2.7 Ch 08 [8.10], p. 97): Doxt-SL (Dr. Reddy's—contains Lactic Acid Bacillus), Microdox-LBX (Micro Labs), Doxy-1 (USV), Minym, Vibromycin — Strengths & Dosage Forms: Oral Capsules / Film-Coated Tablets: 100 mg (also 200 mg loading strength; 40 mg sub-antimicrobial rosacea dose)
Dosage Forms & Available Strengths:
Oral Capsules / Film-Coated Tablets: 100 mg (also 200 mg loading strength; 40 mg sub-antimicrobial rosacea dose)
Routes: Oral / Parenteral / Topical as specified by formulation

3. Mechanism of Action & Pharmacodynamics

Tetracycline Antibiotic (Lipophilic Bacteriostatic 30S Ribosomal Subunit Inhibitor; WHO 'Access' Group) acting on target receptor/enzyme pathways in Antimicrobials — Antibacterial & Antibiotic Agents (Ch 08): clinical efficacy is mediated via Tetracycline Antibiotic (Lipophilic Bacteriostatic 30S Ribosomal Subunit Inhibitor; WHO 'Access' Group) for First-line treatment for Scrub Typhus, Rickettsial infections, and Leptospirosis in India; atypical community-acquired pneumonia and acute exacerbation of COPD; cholera (single 300 mg dose); malaria chemoprophylaxis and severe malaria adjunct (with artesunate/quinine); moderate-to-severe acne vulgaris and rosacea; chlamydial/pelvic inflammatory infections; brucellosis (with rifampicin)..

4. Therapeutic Indications & Evidence-Supported Uses

  • First-line treatment for Scrub Typhus, Rickettsial infections, and Leptospirosis in India
  • atypical community-acquired pneumonia and acute exacerbation of COPD
  • cholera (single 300 mg dose)
  • malaria chemoprophylaxis and severe malaria adjunct (with artesunate/quinine)
  • moderate-to-severe acne vulgaris and rosacea
  • chlamydial/pelvic inflammatory infections
  • brucellosis (with rifampicin)

🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.

5. Educational Dosage Context, Formulations & Administration

Educational Dosing & Regimen Summary: General Adult Reference: 200 mg on Day 1 (100 mg every 12 hours or 200 mg single dose), followed by 100 mg once daily (or 100 mg twice daily in severe infections/scrub typhus/PID) for 5 to 14 days (up to 6–12 weeks in acne). Follow physician prescription.

Administration & Meal Timing: Take WITH food and a FULL BIG GLASS OF WATER (200–250 mL)! (While old tetracyclines were completely blocked by food, doxycycline absorption is reduced by <20% by ordinary food and taking it with a meal prevents severe doxycycline nausea; however, avoid calcium/iron tablets, antacids, and heavy dairy right at the dose time). | Once daily in the morning with breakfast, or twice daily with breakfast and early dinner (at least 1 hour before lying down for bed!).

6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment

Absorption & Disposition:
Absorption, distribution, metabolism, and excretion follow class pharmacokinetic profile; verify patient renal/hepatic function.
Metabolism & Biotransformation:
Renal: SAFEST TETRACYCLINE IN CKD — excreted via non-renal biliary and GI diffusion as an inactive chelate; NO dose adjustment required in any stage of CKD or dialysis (unlike conventional tetracycline). Hepatic: Use with caution in severe hepatic impairment or concurrent hepatotoxic drugs.
Elimination & Renal Adjustment:
Renal: SAFEST TETRACYCLINE IN CKD — excreted via non-renal biliary and GI diffusion as an inactive chelate; NO dose adjustment required in any stage of CKD or dialysis (unlike conventional tetracycline). Hepatic: Use with caution in severe hepatic impairment or concurrent hepatotoxic drugs.
Hepatic Impairment Considerations:
Renal: SAFEST TETRACYCLINE IN CKD — excreted via non-renal biliary and GI diffusion as an inactive chelate; NO dose adjustment required in any stage of CKD or dialysis (unlike conventional tetracycline). Hepatic: Use with caution in severe hepatic impairment or concurrent hepatotoxic drugs.

7. Contraindications, Precautions & High-Risk Warnings

Contraindications & Red-Flag Precautions:
  • Strictly CONTRAINDICATED in Pregnancy (2nd/3rd trimester), Lactation, and Children <8 years of age (except life-threatening Scrub Typhus/Rickettsia where CDC/ICMR permit short courses ≤21 days)—chelates calcium in developing teeth and bones, causing permanent yellow-brown dental enamel staining and bone growth inhibition! High risk of severe Pill-Induced Ulcerative Oesophagitis!Discard expired tetracyclines (degraded epianhydrotetracycline causes Fanconi renal tubular syndrome).

Key Clinical Precautions: Renal: SAFEST TETRACYCLINE IN CKD — excreted via non-renal biliary and GI diffusion as an inactive chelate; NO dose adjustment required in any stage of CKD or dialysis (unlike conventional tetracycline). Hepatic: Use with caution in severe hepatic impairment or concurrent hepatotoxic drugs.

8. Adverse Effects Profile

Common & Mechanism-Related Adverse Effects:
  • Severe epigastric nausea/vomiting (if taken on an empty stomach), corrosive pill oesophagitis (retrosternal chest pain and painful swallowing if capsule sticks in the gullet!), exaggerated phototoxicity / sunburn rash on sun-exposed face, neck, and arms, vaginal candidiasis.
  • Deep oesophageal ulceration and stricture, Idiopathic Intracranial Hypertension (Pseudotumour Cerebri—severe throbbing headache, tinnitus, papilloedema, and blurred/double vision, especially in overweight women or when combined with isotretinoin/Vitamin A!), severe bullous photodermatitis, hepatotoxicity, C. difficile colitis.
Serious / Dose-Limiting Adverse Effects:
  • Monitor for severe hypersensitivity, organ toxicity, or dose-limiting adverse events.

9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions

  • Oral Retinoids (Isotretinoin, Acitretin) & High-Dose Vitamin A: STRICTLY CONTRAINDICATED (synergistic Benign Intracranial Hypertension / Pseudotumour Cerebri & vision loss)
  • Chelation: Calcium, Oral Iron, Zinc, Mg/Al Antacids, Bismuth, and Sucralfate bind doxycycline in gut lumen — separate by 2–3 hours
  • CYP inducers (Carbamazepine, Phenytoin, Barbiturates, chronic Alcohol) shorten half-life (~18h to ~7h)
  • Warfarin: may increase INR (monitor)

10. Clinical Monitoring, Patient Counselling & Storage

Clinical & Laboratory Monitoring: Monitor clinical response, baseline renal/hepatic parameters, and relevant serum biomarkers.

Pharmacist Patient Counselling Points:

  • Patient Counselling Checklist: Mandatory 3-Part 'Oesophagus & Sun' Rule for Doxycycline: 1. Swallow with a full tall glass of water (250 mL) during a meal, and remain sitting or standing upright for at least 30 to 60 minutes afterward—NEVER take a Doxycycline capsule dry or right before lying down to sleep! (Gelatin capsules easily stick to the lower oesophagus and burn a painful ulcer overnight). 2. Keep a 2–3 hour gap from Iron, Calcium, Zinc, and Antacids. 3. Protect skin from direct Indian sunlight (use umbrella/sunscreen), as doxycycline causes rapid sunburn.
  • Meal & Clock Timing Instruction: Take WITH food and a FULL BIG GLASS OF WATER (200–250 mL)! (While old tetracyclines were completely blocked by food, doxycycline absorption is reduced by <20% by ordinary food and taking it with a meal prevents severe doxycycline nausea; however, avoid calcium/iron tablets, antacids, and heavy dairy right at the dose time). (Once daily in the morning with breakfast, or twice daily with breakfast and early dinner (at least 1 hour before lying down for bed!).)
  • Missed Dose Protocol: Take with food and a full glass of water as soon as remembered (unless within 1 hour of bedtime!).
  • Geriatric Dispensing Pearl: Because elderly patients often have reduced salivary flow and slower oesophageal peristalsis, they are at high risk of doxycycline pill oesophagitis—insist on a full glass of water and remaining upright for 1 hour. Safe in elderly CKD patients without renal dose adjustment.

Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Oral Capsules / Film-Coated Tablets: 100 mg (also 200 mg loading strength; 40 mg sub-antimicrobial rosacea dose)

11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)

THE 12-STEP ORAL DRUG JOURNEY THROUGH THE HUMAN BODY (LADME) Note: IV bolus enters Step 6 directly (F = 100%); Sublingual & Transdermal routes bypass Step 4–5 Portal First-Pass Metabolism 1. Oral Administration • Tablet / Capsule swallowed • Gastric emptying to duodenum pH 1.5–3.5 (Stomach) 2. Disintegration & Dissolution • Tablet breaks into granules • API dissolves in GI fluid Noyes-Whitney Dissolution Rate 3. GI Epithelial Absorption • Crosses intestinal villi • Passive / Active / P-gp efflux Small Intestine (Large Surface Area) 4. Portal Circulation • Mesenteric veins → Portal vein • Delivers blood to liver sinusoids Pre-systemic Venous Conduit 5. First-Pass Metabolism • Gut & hepatic CYP450 extraction • High: GTN, Propranolol, Morphine Determines Bioavailability (F = f_a × (1-E_H)) 6. Systemic Circulation • Hepatic vein → IVC → Heart • Unbound vs Albumin-bound drug Only FREE drug is active 7–8. Tissue Distribution (Vd) • Capillary permeation to organs • Blood-Brain & Placental barriers Vd = Dose / C_0 (L or L/kg) 9. Target Site of Action • Receptors (GPCR, Ion channel) • Enzymes & Carrier Transporters Pharmacodynamic Effect (E_max, EC50) 10. Hepatic Biotransformation • Phase I (CYP450 Oxidation/Hydrolysis) • Phase II (Glucuronidation/Sulfation) Converts lipophilic drug → hydrophilic metabolite 11. Renal & Biliary Elimination • Nephron: Filtration + Secretion − Reabsorption • Biliary excretion & Enterohepatic recycling Total Clearance CL_tot = CL_renal + CL_hepatic 12. Excretion from the Body • Urine (Primary polar metabolite route) • Bile/Faeces, Expired Air, Sweat, Milk Elimination Half-Life t1/2 = (0.693 × Vd) / CL
svg-v339-01-adme-12-step-journey — 8.1 Complete 12-Step Journey of an Orally Administered Drug (ADME): Figure 8.1: The 12-step physiological journey of a typical orally administered solid dosage form through Liberation, Absorption, Distribution, Metabolism, and Excretion (LADME). Note: Parenteral (IV), sublingual, and inhalational routes bypass gastrointestinal absorption and/or hepatic first-pass metabolism.

12. Authoritative References, Regulatory Sources & Editorial Disclaimer

Primary Compendial & Guideline Reference: Indian Pharmacist Desk Reference — Professional Edition 2.7 (2026–27) • Ch 08 [8.10] (p. 97)

Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)

Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: HANDBOOK_SOURCE_CONTENT

Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.